China National Biotec Group To Offload Non-Performing Assets
This article was originally published in PharmAsia News
Executive Summary
State-owned China National Biotec Group is gradually offloading its non-performing subsidiaries and those without controlling rights. According to Shanghai United Assets and Equity Exchange, the enterprise has put its wholly owned Tangshan subsidiary on the market for RMB 490,000. Meanwhile, Wuhan Institute of Biologic Products, one of CNBG's six major institutions, will transfer its 30 percent stake in Zhongwei Biotech Company for RMB 510,000. Analysts observe that the move is a prelude to the group's asset clearance and paves the way for its restructuring before going public. Beijing Tiantan Biological Products, CNBG's only listing platform, currently has 51 percent of Changchun Keygen Biological Products and the entire Chengdu Institute of Biological Products. Tiantan is expected to take over Wuhan Institute next. (Click here for more - Chinese Language)
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.